Yale Medicine School: Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease
May 31, 2023
May 31, 2023
NEW HAVEN, Connecticut, May 31 (TNSjou) -- Yale School of Medicine issued the following news:
A new study led by George Goshua, MD, MSc, assistant professor of medicine (hematology), examines the cost effectiveness of gene therapy against standard-of-care treatment for patients with sickle cell disease (SCD), using both conventional cost-effective analysis (CEA) and distributional cost-effective analysis (DCEA) methodology, an approach that takes health equity into quantitative cons . . .
A new study led by George Goshua, MD, MSc, assistant professor of medicine (hematology), examines the cost effectiveness of gene therapy against standard-of-care treatment for patients with sickle cell disease (SCD), using both conventional cost-effective analysis (CEA) and distributional cost-effective analysis (DCEA) methodology, an approach that takes health equity into quantitative cons . . .